# Debate Gate 6: Develop --> Deliver

## Date: 2026-03-21
## Decision: Develop --> Deliver (Production readiness assessment)
## Format: 15-agent structured debate (all Claude, senior tech/biotech roles)
## Prior Gates: Gate 5 (v2.0 Bug Fix, 7/7 GO), Gate 4 (Day 6 Execution), Gate 3 (Selectivity), Gate 2 (Synthesis)

---

## Project Summary for Debate

- **First brightfield InstanSeg model** for CLDN18.2 membrane scoring (zolbetuximab eligibility)
- Self-supervised: DAB membrane staining as ground truth, zero manual annotation
- 84.3M cells across 194 slides (200-slide cohort)
- **16 patients GAINED treatment eligibility, 0 lost** (0.9% baseline --> 30.4% eligible)
- CLSI EP05 reproducibility PASS (all CVs <15%)
- iCAP concordance 3-5x better than baseline
- Pathologist (Dr. Fiset) confirmed 97-98% positivity as accurate
- v2.0 training bug (sigma collapse) resolved via gradual sigma clamp over 5 attempts
- v2.1 produces identical cell counts to v1.0 (ratio=1.00 on 100 test tiles)
- Composite thresholds (0.10/0.20/0.35) are UNCALIBRATED
- 82% at 3+ on controls suggests over-scoring

---

## ML ENGINEERING & TRAINING

---

### Agent 1: VP ML Platform (Google DeepMind Health)

**Perspective:** Training stability, loss function design, optimization theory

**Q1 -- v2.0 Fix: CAUTION**

The gradual sigma clamp (-2.0 to -4.0 over 100 epochs) is an empirically-discovered schedule, not a principled solution. It worked because it kept sigma in a viable basin while the seed head learned enough structure to activate instance_loss. But this is fragile -- the schedule is coupled to dataset size, learning rate, and architecture depth. If any of these change (new tissue type, different scanner), the same schedule may fail. For production, I would want the clamp schedule to be adaptive (e.g., tied to seed head activation rate) rather than hardcoded epoch counts. The fact that 4 out of 5 attempts failed before finding the right schedule is a yellow flag -- this is trial-and-error engineering, not robust design.

**Q2 -- Clinical Readiness: GO**

The eligibility results are ready for pathologist review specifically because they expose uncalibrated thresholds. 16 gained / 0 lost with uncalibrated scoring means the underlying cell detection and membrane measurement are strong. Pathologist review will calibrate the thresholds -- that is the correct workflow order.

**Q3 -- Blind Spot:** The gradual sigma clamp is a training-time intervention only. If someone retrains this model on new data (different cancer type, different IHC stain) without understanding why the schedule exists, they will hit the same collapse. There is no documentation linking the clamp schedule to the underlying vicious cycle.

**Q4 -- Action:** Document the sigma clamp rationale as a formal training protocol, including the failure modes of attempts 1-4, and add automated sigma monitoring that alerts if sigma drops below -3.5 at any epoch.

---

### Agent 2: Principal ML Engineer (Meta FAIR)

**Perspective:** Self-supervised learning, training pipeline robustness

**Q1 -- v2.0 Fix: CAUTION**

The gradual clamp is a valid stabilization technique -- it is conceptually similar to curriculum learning for auxiliary losses. The concern is that v2.1 produces *identical* cell counts to v1.0, meaning the v2.0 pipeline did not improve selectivity despite 8x more training data (10k vs 78k tiles). The fix preserved behavior but did not advance it. This raises the question: is the v1.0 representation ceiling-limited by architecture, or did the clamp schedule prevent the model from exploring a better solution? I would want to see a training run without the clamp but with proper sigma regularization (L2 penalty on log-sigma) to disentangle the two effects.

**Q2 -- Clinical Readiness: GO**

The 16/0 gain/loss ratio is compelling. The key clinical insight is that patients are being MISSED by the baseline, not over-identified. For pathologist review, this asymmetry is exactly what you want to present -- "here are 16 patients your current method misses."

**Q3 -- Blind Spot:** The self-supervised ground truth (DAB staining) encodes staining artifacts as training signal. Variable DAB penetration across tissue blocks means the model's "ground truth" varies systematically between slides. This could create batch effects in eligibility calls that track staining quality rather than biological CLDN18.2 expression.

**Q4 -- Action:** Run a staining-batch analysis: group the 191 slides by staining batch/date and test whether eligibility rates correlate with batch rather than clinical variables. If they do, the model is learning staining variation, not biology.

---

### Agent 3: Staff ML Engineer (NVIDIA Clara)

**Perspective:** Medical imaging model deployment, inference optimization

**Q1 -- v2.0 Fix: GO**

From a deployment standpoint, the fix is sound. The exported TorchScript model (v2.1) produces identical outputs to v1.0, which means the deployment artifact is validated. The training pipeline complexity (gradual clamp, 5 attempts) is irrelevant to the deployed model -- what matters is that the exported .pt file passes inference validation. The seed_threshold=0.5 baked into v1.0 TorchScript is a deployment concern, but since v2.1 matches v1.0, this is a known quantity.

**Q2 -- Clinical Readiness: GO**

84.3M cells on 194 slides demonstrates production-scale inference capability. The model runs on A6000 hardware, which is standard for clinical AI labs. For pathologist review, the per-cell heatmaps are an excellent communication tool.

**Q3 -- Blind Spot:** Inference determinism. TorchScript models can produce slightly different outputs on different GPU architectures (A6000 vs A100 vs consumer GPUs) due to floating-point non-determinism in CUDA kernels. If this model moves to a different compute environment (hospital GPU, cloud), the cell counts may shift. No one has tested cross-GPU reproducibility.

**Q4 -- Action:** Run the 100-tile validation on a second GPU architecture (even a consumer card) and confirm cell count ratio remains 1.00 +/- 0.02. If not, pin CUDA deterministic mode or document the variance.

---

### Agent 4: Senior Research Scientist (Allen Institute for AI)

**Perspective:** Reproducibility, scientific rigor, methodological soundness

**Q1 -- v2.0 Fix: CAUTION**

Five training attempts with one success is a 20% hit rate. In a reproducibility context, this is concerning. Can the successful training run (attempt 5) be reproduced from the same random seed? If not, the gradual clamp may be necessary but not sufficient -- there could be stochastic factors (data ordering, weight initialization) that also contributed. I would want to see 3 independent replications of attempt 5 with different seeds to confirm the clamp schedule is robust. Without this, we are deploying a model that we know how to train once, but cannot guarantee we could train again.

**Q2 -- Clinical Readiness: CAUTION**

The eligibility results are scientifically ready for pathologist review, but the presentation must be extremely careful. "16 gained, 0 lost" sounds like a clinical trial result, but this is with uncalibrated thresholds. The correct framing is: "Our cell detection identifies 16 additional patients with substantial CLDN18.2 membrane staining that the baseline pipeline missed. Whether these patients meet clinical eligibility thresholds requires pathologist calibration." Misframing this as a diagnostic accuracy result would be scientifically irresponsible.

**Q3 -- Blind Spot:** There is no external validation set. All 191 slides come from the same institution (MUHC), same scanner, same staining protocol. Generalizability to other sites is completely unknown. A model that works at MUHC but fails at other sites is not clinically useful for a multi-center treatment decision.

**Q4 -- Action:** Before any publication or regulatory submission, obtain 20-30 slides from a second institution with a different scanner and staining protocol. Run inference and compare cell counts / eligibility rates. This is the minimum for a generalizability claim.

---

## CLINICAL AI & PATHOLOGY

---

### Agent 5: CTO (Paige AI)

**Perspective:** Pathology AI at scale, FDA clearance pathway, production systems

**Q1 -- v2.0 Fix: GO**

We have seen worse. The gradual clamp is a pragmatic engineering solution that achieved the objective: a deployable model with validated outputs. In our experience at Paige, the training journey matters less than the deployment artifact. The model passes inference validation (identical to v1.0), passes CLSI EP05 reproducibility, and has pathologist endorsement. The 5-attempt training history is a concern for the training pipeline, not the model itself. Ship v2.1 with v1.0-equivalent performance while improving the pipeline for v3.0.

**Q2 -- Clinical Readiness: GO**

This is exactly the right stage for pathologist review. You have quantitative results (84.3M cells, 16 gained/0 lost) with clear caveats (uncalibrated thresholds, single institution). The pathologist's job is to calibrate -- that is not something you do before showing them data. The heatmaps with continuous DAB scores and discrete grades are the right communication format.

**Q3 -- Blind Spot:** FDA/Health Canada regulatory classification. If this tool influences treatment decisions (zolbetuximab eligibility), it is a Software as Medical Device (SaMD) Class II or III depending on jurisdiction. The self-supervised training approach (no manual annotation) is novel and has no predicate device. Regulatory agencies may require a locked dataset with manual annotation as ground truth for the validation study, even if the model was trained self-supervised.

**Q4 -- Action:** Engage McGill tech transfer and a regulatory consultant NOW, before publishing any results. A single premature publication could compromise patent claims and constrain the regulatory pathway.

---

### Agent 6: VP Computational Pathology (Roche Diagnostics)

**Perspective:** Companion diagnostics development, VENTANA scoring standards

**Q1 -- v2.0 Fix: CAUTION**

The fix is adequate for a research tool but inadequate for a companion diagnostic. In our CDx development pipeline, a training procedure that succeeds on 1 of 5 attempts would fail our design control requirements (ISO 13485). The training process itself must be validated -- not just the output model. If you cannot reliably reproduce the training, you cannot file a CDx with any regulatory body. The gradual clamp must be formalized as a standard operating procedure with defined acceptance criteria at each stage.

**Q2 -- Clinical Readiness: GO**

The eligibility data is appropriate for pathologist review. I specifically note that the 82% at 3+ on iCAP controls confirms over-scoring, which is the expected direction for an uncalibrated system. The pathologist calibration session should focus on establishing the 2+/3+ boundary using the continuous DAB measurements, not the discrete grade calls. Present the pathologist with continuous data and let them draw the line.

**Q3 -- Blind Spot:** The bar-filter membrane measurement (gap=+0.127) has only been validated against the model's own cell boundaries via boundary_validation.json, but the boundary_validation.json file shows all zeros -- meaning the compartment validation tests were never completed or returned no data. The membrane measurement pipeline may be measuring the wrong compartment.

**Q4 -- Action:** Complete the boundary validation tests. Specifically: on 50 manually-selected cells with clear membrane staining, verify that membrane_dab_mean > cytoplasm_dab_mean > nucleus_dab_mean. If this ordering does not hold, the scoring pipeline is fundamentally flawed regardless of cell detection quality.

---

### Agent 7: Director Clinical AI (PathAI)

**Perspective:** Clinical validation workflows, study design, AI-pathologist collaboration

**Q1 -- v2.0 Fix: GO**

The fix achieves functional equivalence with v1.0, which is the minimum bar. From a clinical validation standpoint, the training procedure is an implementation detail -- what matters is the model's performance on held-out data with pathologist ground truth. The v2.0 training history informs the R&D pipeline but does not affect the clinical validation of the deployed model.

**Q2 -- Clinical Readiness: CAUTION**

Ready for pathologist review, but NOT ready for clinical decision-making. The distinction is critical. Pathologist review means: "Dr. Fiset reviews the model's per-cell measurements on 30-50 cases and provides calibration feedback." Clinical decision-making means: "The model's output directly influences whether a patient receives zolbetuximab." The gap between these two is at least 6 months of formal validation. Present the 16-patient gain as a hypothesis, not a conclusion.

**Q3 -- Blind Spot:** Selection bias in the cohort. The 200 slides were selected from a clinical archive -- were they consecutive patients, or were they selected based on availability, tissue quality, or prior IHC results? If non-consecutive, the 30.4% eligibility rate could be inflated or deflated relative to the true population rate. This matters for the clinical impact narrative.

**Q4 -- Action:** Document the cohort selection criteria and confirm whether the 200 slides represent consecutive patients from a defined time period. If not, calculate the selection bias risk and present it alongside the eligibility results.

---

### Agent 8: Head of Digital Pathology (Leica/Aperio)

**Perspective:** Scanner integration, IHC scoring standardization, image quality

**Q1 -- v2.0 Fix: GO**

The model deployment artifact is scanner-agnostic at the tile level (512x512 at 0.5 um/px). The training fix does not affect scanner compatibility. The bar-filter membrane measurement at 10px FWHM with peak 4px inside cell edge is consistent with our Aperio membrane scoring algorithms for HER2 and other membranous markers.

**Q2 -- Clinical Readiness: GO**

The 8192px heatmap resolution is appropriate for pathologist review. The heatmap gap issue (7.8% from tile coverage, not rendering) has been identified and documented. For clinical presentation, overlay the heatmaps on the WSI at the tissue boundary level so pathologists can contextualize the gaps.

**Q3 -- Blind Spot:** Scanner calibration drift. The 200-slide cohort was scanned over what time period? If months or years, scanner color calibration may have drifted, creating a temporal confound in DAB quantification. A slide scanned in January 2024 and September 2025 on the same scanner may have different RGB profiles for the same DAB concentration. This affects the self-supervised ground truth and the inference-time measurements.

**Q4 -- Action:** Check the scanner calibration logs for the scanning period. If calibration data is unavailable, include scanning date as a covariate in the eligibility analysis and test for temporal trends.

---

## BIOTECH & DRUG DEVELOPMENT

---

### Agent 9: Head Biomarker Strategy (Astellas Pharma)

**Perspective:** CLDN18.2 domain expertise, zolbetuximab clinical development

**Q1 -- v2.0 Fix: GO**

From a biomarker strategy perspective, the training methodology is an implementation detail. What matters is: does the model accurately identify CLDN18.2 membrane expression? The answer appears to be yes, validated by pathologist review and iCAP concordance. The v2.1 model matches v1.0, which Dr. Fiset confirmed as accurate. We care about the output, not the training journey.

**Q2 -- Clinical Readiness: CAUTION**

The 16 gained / 0 lost is directionally compelling but must be contextualized correctly. Zolbetuximab eligibility in the SPOTLIGHT/GLOW trials used VENTANA CLDN18 (43-14A) with a trained pathologist scoring >= 75% of tumor cells at moderate-to-strong (2+/3+) membrane staining. Your composite thresholds (0.10/0.20/0.35) are NOT equivalent to the VENTANA scoring criteria. Presenting these results as "eligibility" without this caveat could create misalignment with our clinical development program. Use "preliminary scoring" or "screening" instead of "eligibility" until thresholds are calibrated to VENTANA concordance.

**Q3 -- Blind Spot:** The VENTANA 43-14A assay was developed and validated as an integrated system (antibody + staining protocol + scoring guide). Your model replaces only the scoring component. If the upstream staining protocol at MUHC differs from the VENTANA reference protocol (different antibody clone, different retrieval, different chromogen), the model's measurements are not directly comparable to SPOTLIGHT/GLOW trial data. Has the staining protocol been verified against the VENTANA reference?

**Q4 -- Action:** Obtain the VENTANA 43-14A technical data sheet and verify that MUHC's staining protocol matches on: antibody clone, antigen retrieval method, chromogen system, and counterstain. Document any deviations. This is prerequisite to claiming zolbetuximab eligibility alignment.

---

### Agent 10: VP Translational Medicine (Merck KGaA)

**Perspective:** Companion diagnostic development lifecycle, CDx-drug co-development

**Q1 -- v2.0 Fix: CAUTION**

In CDx development, the training procedure is part of the design history file and is subject to regulatory review. A procedure that required 5 iterations with 4 failures would raise questions in a design review under EU IVDR or FDA PMA. The fix works, but the design control documentation must explain WHY it works (mathematical rationale for the clamp schedule) and include acceptance criteria for future retraining. Without this, the model cannot enter a CDx development pathway.

**Q2 -- Clinical Readiness: GO**

For pathologist review -- absolutely yes. This is a standard step in CDx development: generate preliminary data, present to clinical key opinion leaders, incorporate feedback into threshold calibration. The 16/0 gain/loss ratio is the type of signal that justifies continued investment in the diagnostic program.

**Q3 -- Blind Spot:** Analytical sensitivity vs. clinical sensitivity. The model detects 84.3M cells, but the clinical question is whether it correctly identifies the SUBSET of patients who will respond to zolbetuximab. High cell detection sensitivity does not guarantee clinical sensitivity. The 16 "gained" patients may include false positives who would not respond to treatment. Without treatment outcome data, you cannot distinguish analytical accuracy from clinical utility.

**Q4 -- Action:** Design a retrospective concordance study: identify patients in the MUHC cohort who received zolbetuximab (or similar anti-CLDN18.2 therapy) and correlate the model's scoring with treatment response. Even 5-10 cases would provide preliminary clinical sensitivity data.

---

### Agent 11: Director Biomarker Development (AstraZeneca)

**Perspective:** IHC assay development and validation, biomarker cutoff determination

**Q1 -- v2.0 Fix: GO**

The gradual sigma clamp is essentially a form of constrained optimization -- limiting the parameter space to prevent degenerate solutions. This is standard practice in assay development: we constrain calibration curves, we set floor/ceiling on signal amplification, we clamp exposure times. The principle is sound. The execution (5 attempts) reflects the exploratory nature of the constraint identification, not a fundamental flaw.

**Q2 -- Clinical Readiness: CAUTION**

The uncalibrated thresholds are the single biggest gap. In IHC assay development, cutoff determination follows a formal protocol: (1) stain a well-characterized cohort with known expression levels, (2) have 3+ pathologists independently score, (3) derive cutoffs from inter-reader concordance data. The 82% at 3+ on controls proves the current thresholds are not clinically meaningful. Present the continuous measurements to the pathologist and derive cutoffs from their scoring -- do NOT present the current grade assignments.

**Q3 -- Blind Spot:** No inter-reader variability data. Dr. Fiset is a single pathologist. IHC scoring for treatment decisions requires demonstration of inter-reader reproducibility (typically kappa >= 0.6 among 3+ readers). A model calibrated to one pathologist may not generalize to another pathologist's scoring behavior. This is a known problem in CLDN18.2 specifically -- published studies show high inter-reader variability for membrane scoring.

**Q4 -- Action:** Recruit 2 additional GI pathologists to independently score 30 cases using the model's continuous measurements. Calculate inter-reader kappa. This is mandatory before any cutoff can be considered validated.

---

## INFRASTRUCTURE & DEPLOYMENT

---

### Agent 12: Principal SRE (Google Cloud Healthcare)

**Perspective:** Production reliability, monitoring, incident response

**Q1 -- v2.0 Fix: GO**

The deployed model (TorchScript .pt file) is a static artifact. The training pipeline complexity does not affect production reliability. From an SRE perspective, the relevant questions are: Does inference complete reliably? Is latency predictable? Are outputs deterministic? The CLSI EP05 reproducibility PASS with CVs <15% answers all three.

**Q2 -- Clinical Readiness: GO**

For pathologist review, the system does not need production-grade reliability guarantees. It needs to produce accurate, reproducible results on demand. The 194-slide cohort completion demonstrates this capability.

**Q3 -- Blind Spot:** No monitoring or alerting infrastructure. If the model produces anomalous results on a new slide (e.g., zero cells detected due to a tissue processing artifact), there is no automated detection. In production, you need anomaly detection on per-slide cell counts, per-slide DAB distributions, and inference latency. A slide with 0 cells should trigger an alert, not silently pass through.

**Q4 -- Action:** Implement a post-inference validation check: for each slide, verify cell count > minimum threshold (e.g., 1000 cells), DAB distribution is non-degenerate (std > 0.01), and inference time is within 2x the median. Flag anomalies for manual review.

---

### Agent 13: Staff Engineer, ML Infrastructure (Databricks)

**Perspective:** Training pipeline robustness, data pipeline integrity, MLOps

**Q1 -- v2.0 Fix: CAUTION**

The 5-attempt training history reveals a fragile pipeline. In MLOps terms, this training procedure is not idempotent -- the same inputs do not reliably produce the same output. The gradual clamp is a workaround for a deeper architectural issue (InstanSeg's instance_loss dependency on seed predictions). For production ML infrastructure, I would want: (a) the clamp schedule parameterized in a config file, not hardcoded, (b) automated training health checks that detect sigma collapse within 5 epochs and abort, (c) a training contract that specifies acceptance criteria (F1 > 0.3, sigma_mean > -4.0, cell count on reference tiles > 100).

**Q2 -- Clinical Readiness: GO**

The inference pipeline (not the training pipeline) is what pathologists interact with. The inference pipeline produced 84.3M cells across 194 slides without failures. This is production-ready for pathologist review.

**Q3 -- Blind Spot:** Data provenance and lineage. Can you trace each of the 84.3M cells back to its source tile, source slide, and scanning session? If a pathologist questions a specific cell's measurement, can you reproduce the exact tile and show the model's prediction? Without data lineage, debugging clinical disagreements is impossible.

**Q4 -- Action:** Build a data lineage system: for each cell, store (slide_id, tile_coordinates, cell_id, model_version, inference_timestamp). This enables drill-down from cohort-level results to individual cell predictions.

---

## REGULATORY & QUALITY

---

### Agent 14: Head of Software Quality (Hologic/Leica)

**Perspective:** IVD software validation, design controls, quality management systems

**Q1 -- v2.0 Fix: NO-GO (for production release) / GO (for research use)**

Let me be precise. For research use and pathologist review, the model is acceptable. For production release as an IVD or clinical decision support tool, the training procedure fails multiple design control requirements under IEC 62304 and ISO 13485: (a) no formal design input document specifying sigma clamp requirements, (b) no traceability from the clamp schedule to a design requirement, (c) no verified procedure for reproducing the training (4/5 failure rate), (d) no formal verification that the model meets its intended use specifications. These are not optional for a medical device -- they are regulatory requirements.

**Q2 -- Clinical Readiness: CAUTION**

Ready for pathologist review as a research tool. Not ready for any clinical workflow integration. The distinction matters because if this tool enters clinical practice without proper validation, the institution assumes liability. The REB promises "quantitative membranous staining metrics" -- ensure the deliverables match the REB scope exactly. No more, no less.

**Q3 -- Blind Spot:** Software lifecycle documentation. There is no formal software requirements specification, no design verification protocol, no risk analysis (ISO 14971), and no validation protocol. These documents must exist before the software can be used in any regulated context. Starting them now is cheaper than retrofitting later.

**Q4 -- Action:** Create a preliminary Software Requirements Specification (SRS) that documents: intended use, input specifications (slide format, scanner requirements, staining protocol), output specifications (cell measurements, grade assignments), and performance requirements (sensitivity, specificity, reproducibility targets). This document frames all subsequent validation work.

---

### Agent 15: Director Regulatory Affairs (Roche Diagnostics)

**Perspective:** CDx regulatory pathways, FDA/Health Canada submissions, predicate devices

**Q1 -- v2.0 Fix: CAUTION**

The training methodology is part of the regulatory submission package for any AI-based medical device. The gradual sigma clamp is novel and has no precedent in FDA-cleared or Health Canada-licensed pathology AI devices. This is neither positive nor negative -- it means there is no predicate, and the submission will require more extensive technical documentation. The 5-attempt training history must be documented honestly in the design history file. Regulatory agencies appreciate transparency about development challenges more than they penalize them.

**Q2 -- Clinical Readiness: GO**

For pathologist review as part of a development program -- absolutely. This is standard CDx development practice: preliminary analytical data reviewed by clinical experts before formal validation studies. The uncalibrated thresholds are expected at this stage. Regulators understand that cutoff determination is iterative.

**Q3 -- Blind Spot:** The patent situation. McGill tech transfer has not been consulted. If results are published or presented at conferences before a patent filing, the novelty window closes. For a self-supervised training approach on brightfield IHC, this could be a significant IP position. Regulatory submissions can be filed without compromising IP, but publications and conference presentations cannot be undone.

**Q4 -- Action:** Schedule a meeting with McGill tech transfer within 2 weeks. Provide them with: (a) a non-technical summary of the innovation (self-supervised membrane scoring), (b) the clinical data (16 patients gained eligibility), (c) a list of planned publications/presentations. Let them advise on filing strategy before ANY public disclosure.

---

## CONSENSUS SYNTHESIS

### Vote Tally

| Agent | Role | v2.0 Fix | Clinical Readiness |
|-------|------|----------|-------------------|
| 1. VP ML Platform (DeepMind) | Training stability | CAUTION | GO |
| 2. Principal ML (Meta FAIR) | Self-supervised learning | CAUTION | GO |
| 3. Staff ML (NVIDIA Clara) | Deployment | GO | GO |
| 4. Sr Research Sci (AI2) | Reproducibility | CAUTION | CAUTION |
| 5. CTO (Paige AI) | Pathology AI at scale | GO | GO |
| 6. VP CompPath (Roche Dx) | Companion diagnostics | CAUTION | GO |
| 7. Dir Clinical AI (PathAI) | Clinical validation | GO | CAUTION |
| 8. Head DigPath (Leica/Aperio) | Scanner integration | GO | GO |
| 9. Head Biomarker (Astellas) | CLDN18.2 domain | GO | CAUTION |
| 10. VP TransMed (Merck KGaA) | CDx development | CAUTION | GO |
| 11. Dir Biomarker (AstraZeneca) | IHC assay development | GO | CAUTION |
| 12. Principal SRE (Google Cloud) | Production reliability | GO | GO |
| 13. Staff Eng (Databricks) | ML Infrastructure | CAUTION | GO |
| 14. Head SW Quality (Hologic) | IVD validation | NO-GO* | CAUTION |
| 15. Dir Regulatory (Roche Dx) | Regulatory pathways | CAUTION | GO |

**v2.0 Fix Votes:** 7 GO / 7 CAUTION / 1 NO-GO*
**Clinical Readiness Votes:** 10 GO / 5 CAUTION / 0 NO-GO

*Agent 14 voted NO-GO for production release but GO for research use. Since pathologist review is the immediate deliverable (research context), this is effectively a conditional CAUTION.

### Adjusted Summary

| Question | GO | CAUTION | NO-GO |
|----------|-----|---------|-------|
| v2.0 Fix (production) | 7 (47%) | 7 (47%) | 1 (7%) |
| Clinical Readiness (pathologist review) | 10 (67%) | 5 (33%) | 0 (0%) |

---

### Top 5 Risks by Severity

**1. UNCALIBRATED THRESHOLDS (CRITICAL)**
*Flagged by: Agents 6, 9, 11, 14*
The composite thresholds (0.10/0.20/0.35) produce 82% at 3+ on controls -- clearly over-scoring. These thresholds are NOT equivalent to VENTANA CLDN18 (43-14A) scoring criteria. Presenting grade assignments (0/1+/2+/3+) with uncalibrated thresholds risks misinterpretation as validated clinical scores. The term "eligibility" should be replaced with "preliminary screening" until calibration is complete.
**Severity: BLOCKING for clinical use, non-blocking for pathologist review if caveated**

**2. SINGLE-INSTITUTION, SINGLE-READER VALIDATION (HIGH)**
*Flagged by: Agents 4, 7, 11*
All 191 slides are from MUHC. One pathologist (Dr. Fiset) validated the results. No inter-reader variability data. No external validation set. Published IHC scoring standards require multi-reader concordance (kappa >= 0.6 among 3+ readers). Generalizability is completely unknown.
**Severity: BLOCKING for publication/submission, non-blocking for internal pathologist review**

**3. TRAINING PIPELINE FRAGILITY (MODERATE-HIGH)**
*Flagged by: Agents 1, 2, 4, 6, 10, 13, 14*
The gradual sigma clamp required 5 attempts (20% success rate). The schedule is hardcoded, dataset-specific, and lacks theoretical justification. No formal reproduction testing. The training procedure would fail ISO 13485 design control requirements. Risk of collapse recurrence if any training parameter changes.
**Severity: Non-blocking for v2.1 deployment (model artifact validated), BLOCKING for pipeline reuse**

**4. PATENT AND IP EXPOSURE (MODERATE-HIGH)**
*Flagged by: Agents 5, 15*
Self-supervised brightfield membrane scoring with no manual annotation is a novel approach with potential IP value. McGill tech transfer has not been consulted. Any public disclosure (publication, conference, preprint) before patent filing could compromise the novelty window. The Astellas funding relationship may create additional IP obligations.
**Severity: BLOCKING for any public disclosure**

**5. BOUNDARY VALIDATION INCOMPLETE (MODERATE)**
*Flagged by: Agent 6*
The boundary_validation.json file contains all zeros -- the compartment intensity validation tests (membrane > cytoplasm > nucleus DAB ordering) were never completed or produced no results. Without confirming that the bar-filter is actually measuring membrane DAB correctly, the entire scoring pipeline rests on an unverified assumption.
**Severity: BLOCKING for scoring confidence, non-blocking for cell detection**

---

### Top 5 Recommended Actions by Priority

**1. COMPLETE BOUNDARY VALIDATION (Before pathologist review)**
*Recommended by: Agent 6*
On 50+ manually-selected cells with clear membrane staining, verify membrane_dab_mean > cytoplasm_dab_mean > nucleus_dab_mean. This confirms the measurement pipeline is targeting the correct compartment. The all-zeros in boundary_validation.json must be resolved. If the ordering does not hold, the scoring pipeline needs fundamental correction before any clinical presentation.

**2. PATHOLOGIST CALIBRATION SESSION (Week 1)**
*Recommended by: Agents 6, 9, 11*
Present Dr. Fiset with CONTINUOUS DAB measurements (not discrete grades) on 30-50 cases. Let the pathologist establish the 2+/3+ boundary from the continuous data. Do NOT present the 0.10/0.20/0.35 thresholds as meaningful. Use the term "preliminary cell detection results" rather than "eligibility scoring." Recruit 2 additional GI pathologists for inter-reader concordance.

**3. CONTACT McGILL TECH TRANSFER (This week)**
*Recommended by: Agents 5, 15*
Schedule a meeting within 2 weeks. Provide a non-technical summary of the innovation (self-supervised IHC membrane scoring, no manual annotation, first brightfield InstanSeg model). Include the clinical impact data (16 patients gained eligibility). Obtain guidance on patent filing strategy BEFORE any public disclosure (conference abstract, publication, preprint).

**4. DOCUMENT TRAINING PROTOCOL (Week 2)**
*Recommended by: Agents 1, 10, 13, 14*
Create a formal training protocol document covering: (a) the sigma collapse failure mode and its root cause, (b) the gradual clamp schedule with mathematical rationale, (c) automated training health checks (sigma monitoring, F1 tracking, early abort criteria), (d) acceptance criteria for trained models (cell count on reference tiles, sigma range, F1 threshold). This is prerequisite for any future retraining or regulatory submission.

**5. STAINING BATCH ANALYSIS (Week 2-3)**
*Recommended by: Agents 2, 8*
Group the 191 slides by staining batch/date and scanning date. Test whether eligibility rates correlate with batch variables (staining date, scanner calibration state) rather than clinical variables (tumor grade, CLDN18.2 expression). If batch effects exist, they undermine the clinical validity of the eligibility results. Include scanning date as a covariate in the eligibility analysis.

---

### BLOCKING Issues (Must Resolve Before Delivery)

| # | Issue | Blocking For | Resolution |
|---|-------|-------------|------------|
| 1 | Boundary validation incomplete (all zeros) | Pathologist presentation of scoring results | Run compartment intensity validation on 50+ cells |
| 2 | Uncalibrated thresholds presented as "eligibility" | Any clinical communication | Replace "eligibility" with "preliminary screening" in all outputs |
| 3 | McGill tech transfer not consulted | Any public disclosure | Schedule meeting this week |
| 4 | Single-reader validation | Publication or regulatory submission | Recruit 2 additional pathologists (not blocking for Dr. Fiset review) |

---

### FINAL VERDICT

```
+------------------------------------------------------------------+
|                                                                  |
|   DECISION:  CONDITIONAL GO                                      |
|                                                                  |
|   For: Pathologist review (research context)                     |
|   NOT for: Clinical deployment, publication, regulatory filing   |
|                                                                  |
|   Confidence: 10/15 GO clinical readiness                        |
|               7/15 GO v2.0 fix (7 CAUTION, 1 NO-GO)             |
|                                                                  |
|   BEFORE pathologist review:                                     |
|     1. Fix boundary_validation.json (all zeros)                  |
|     2. Replace "eligibility" with "preliminary screening"        |
|     3. Present continuous DAB measurements, not grades            |
|                                                                  |
|   BEFORE any public disclosure:                                  |
|     4. Contact McGill tech transfer (patent window)              |
|                                                                  |
|   BEFORE publication/submission:                                 |
|     5. Multi-reader concordance (3 pathologists, 30 cases)       |
|     6. External validation (20+ slides from second site)         |
|     7. Formal training protocol documentation                    |
|     8. Staining batch analysis                                   |
|                                                                  |
|   The model's cell detection performance is strong               |
|   (84.3M cells, 16 gained/0 lost, EP05 PASS).                   |
|   The SCORING pipeline needs calibration and validation.         |
|   The TRAINING pipeline needs documentation and hardening.       |
|   The IP position needs immediate protection.                    |
|                                                                  |
|   Bottom line: The cell detection engine is ready to show        |
|   a pathologist. The scoring thresholds are not ready to         |
|   influence patient care. Know the difference.                   |
|                                                                  |
+------------------------------------------------------------------+
```

---

### Comparison to Prior Gates

| Gate | Date | Decision | Key Concern | Status |
|------|------|----------|-------------|--------|
| Gate 2 | Day 3 | GO | Selectivity validation needed | RESOLVED (33x DAB selectivity) |
| Gate 3 | Day 4 | CAUTION | Heatmap gaps, threshold calibration | PARTIALLY RESOLVED (gaps documented, thresholds still uncalibrated) |
| Gate 4 | Day 6 | GO w/conditions | Uncalibrated grades, v2.0 training | v2.0 FIXED, grades still uncalibrated |
| Gate 5 | Day 7 | GO (7/7) | Sigma collapse fix | RESOLVED (v2.1 matches v1.0) |
| **Gate 6** | **Day 7** | **CONDITIONAL GO** | **Boundary validation, threshold calibration, IP protection** | **ACTIVE** |

The project has systematically addressed technical risks (cell detection, training stability, reproducibility) and is now confronting the expected next-stage risks: clinical validation, regulatory preparation, and IP protection. This is healthy progression.

---

*Debate conducted by Claude Opus 4.6 (1M context) simulating 15 agents with senior tech/biotech roles. All perspectives are synthesized from domain expertise in pathology AI, companion diagnostics, ML engineering, regulatory affairs, and biomarker development.*
